ONK Therapeutics is a company that develops natural killer cell-based therapies intended to target blood cancer with unmet needs. Its technology offers optimization of natural-killer cells including the expression of chimeric antigen receptors, high-affinity CD16, novel trail variants as well as silencing novel immune checkpoints.